SG11201607287XA - Recombinant isfahan viral vectors - Google Patents
Recombinant isfahan viral vectorsInfo
- Publication number
- SG11201607287XA SG11201607287XA SG11201607287XA SG11201607287XA SG11201607287XA SG 11201607287X A SG11201607287X A SG 11201607287XA SG 11201607287X A SG11201607287X A SG 11201607287XA SG 11201607287X A SG11201607287X A SG 11201607287XA SG 11201607287X A SG11201607287X A SG 11201607287XA
- Authority
- SG
- Singapore
- Prior art keywords
- viral vectors
- isfahan
- recombinant
- recombinant isfahan
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946734P | 2014-03-01 | 2014-03-01 | |
| PCT/US2015/018156 WO2015134332A2 (en) | 2014-03-01 | 2015-02-27 | Recombinant isfahan viral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607287XA true SG11201607287XA (en) | 2016-09-29 |
Family
ID=54055975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607287XA SG11201607287XA (en) | 2014-03-01 | 2015-02-27 | Recombinant isfahan viral vectors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9932564B2 (en) |
| EP (1) | EP3113795B1 (en) |
| JP (3) | JP2017508465A (en) |
| KR (1) | KR102416194B1 (en) |
| CN (1) | CN106794240A (en) |
| AU (1) | AU2015225553B2 (en) |
| CA (1) | CA2941261A1 (en) |
| DK (1) | DK3113795T3 (en) |
| ES (1) | ES2749381T3 (en) |
| IL (2) | IL247545B (en) |
| MX (1) | MX369776B (en) |
| SG (1) | SG11201607287XA (en) |
| WO (1) | WO2015134332A2 (en) |
| ZA (1) | ZA201606036B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Zika virus rna vaccines |
| CA3075990A1 (en) * | 2017-09-15 | 2019-03-21 | Ohio State Innovation Foundation | Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections |
| US20210290705A1 (en) * | 2018-07-17 | 2021-09-23 | Yale University | Methods for treatment of cancer using chikungunya-vsv chimeric virus |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| WO2004093906A1 (en) | 2003-03-26 | 2004-11-04 | Wyeth | Immunogenic composition and methods |
| CA2799469C (en) * | 2004-04-09 | 2016-06-07 | Wyeth | Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| KR101255016B1 (en) | 2004-04-09 | 2013-04-17 | 와이어쓰 엘엘씨 | Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof |
| US8481023B2 (en) * | 2006-09-15 | 2013-07-09 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| MX342449B (en) * | 2007-08-03 | 2016-09-29 | Pasteur Institut | Lentiviral gene transfer vectors and their medicinal applications. |
| CA2717499A1 (en) * | 2008-03-14 | 2009-09-17 | Sanofi Pasteur Biologics Co. | Replication-defective flavivirus vaccines and vaccine vectors |
| US9707285B2 (en) * | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| ES2533345T3 (en) * | 2009-06-08 | 2015-04-09 | The University Of Western Ontario | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens |
| ES2788198T3 (en) | 2010-05-14 | 2020-10-20 | Univ Oregon Health & Science | Recombinant hCMV and hCMV vectors encoding a heterologous antigen isolated from hepatitis B virus and uses thereof |
| US20130095556A1 (en) * | 2011-09-21 | 2013-04-18 | International Aids Vaccine Initiative | Novel vesicular stomatitis virus and virus rescue system |
-
2015
- 2015-02-27 MX MX2016011300A patent/MX369776B/en active IP Right Grant
- 2015-02-27 CA CA2941261A patent/CA2941261A1/en active Pending
- 2015-02-27 AU AU2015225553A patent/AU2015225553B2/en active Active
- 2015-02-27 DK DK15758863.3T patent/DK3113795T3/en active
- 2015-02-27 SG SG11201607287XA patent/SG11201607287XA/en unknown
- 2015-02-27 ES ES15758863T patent/ES2749381T3/en active Active
- 2015-02-27 EP EP15758863.3A patent/EP3113795B1/en active Active
- 2015-02-27 WO PCT/US2015/018156 patent/WO2015134332A2/en active Application Filing
- 2015-02-27 US US15/122,695 patent/US9932564B2/en active Active
- 2015-02-27 CN CN201580026511.3A patent/CN106794240A/en active Pending
- 2015-02-27 JP JP2016555578A patent/JP2017508465A/en active Pending
- 2015-02-27 KR KR1020167027395A patent/KR102416194B1/en active IP Right Grant
-
2016
- 2016-08-30 IL IL247545A patent/IL247545B/en unknown
- 2016-08-31 ZA ZA2016/06036A patent/ZA201606036B/en unknown
-
2020
- 2020-02-03 JP JP2020015937A patent/JP7454393B2/en active Active
-
2022
- 2022-01-31 IL IL290258A patent/IL290258A/en unknown
- 2022-06-14 JP JP2022095401A patent/JP2022126723A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102416194B1 (en) | 2022-07-04 |
| EP3113795B1 (en) | 2019-07-10 |
| EP3113795A4 (en) | 2017-07-26 |
| WO2015134332A3 (en) | 2016-01-28 |
| EP3113795A2 (en) | 2017-01-11 |
| JP2020078318A (en) | 2020-05-28 |
| ZA201606036B (en) | 2020-02-26 |
| IL247545B (en) | 2022-03-01 |
| CN106794240A (en) | 2017-05-31 |
| DK3113795T3 (en) | 2019-10-21 |
| CA2941261A1 (en) | 2015-09-11 |
| US9932564B2 (en) | 2018-04-03 |
| WO2015134332A2 (en) | 2015-09-11 |
| IL290258A (en) | 2022-04-01 |
| IL247545A0 (en) | 2016-11-30 |
| AU2015225553A1 (en) | 2016-09-15 |
| AU2015225553B2 (en) | 2020-02-27 |
| MX369776B (en) | 2019-11-21 |
| KR20160135740A (en) | 2016-11-28 |
| JP2017508465A (en) | 2017-03-30 |
| JP2022126723A (en) | 2022-08-30 |
| US20170067027A1 (en) | 2017-03-09 |
| JP7454393B2 (en) | 2024-03-22 |
| ES2749381T3 (en) | 2020-03-20 |
| MX2016011300A (en) | 2017-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201401707D0 (en) | Adeno-associated viral vectors | |
| EP3221456A4 (en) | Genome-modified recombinant adeno-associated virus vectors | |
| IL290258A (en) | Recombinant isfahan viral vectors | |
| GB201509578D0 (en) | Vectors | |
| GB201418562D0 (en) | Peptides | |
| GB201520559D0 (en) | Peptides | |
| GB201508337D0 (en) | Novel peptides | |
| ZA201801091B (en) | Recombinant orf virus vector | |
| GB201520536D0 (en) | Peptides | |
| GB201401877D0 (en) | Peptides | |
| GB201520546D0 (en) | Peptides | |
| GB201520545D0 (en) | Peptides | |
| GB201520550D0 (en) | Peptides | |
| GB201520544D0 (en) | Peptides | |
| GB201520541D0 (en) | Peptides | |
| GB201520539D0 (en) | Peptides | |
| GB201520543D0 (en) | Peptides | |
| HK1253316A1 (en) | Peptides | |
| GB201503483D0 (en) | Novel Antimmicrobial Peptides | |
| GB201520548D0 (en) | Peptides | |
| GB201520558D0 (en) | Peptides | |
| GB201520557D0 (en) | Peptides | |
| GB201520542D0 (en) | Peptides | |
| GB201520554D0 (en) | Peptides | |
| GB201520537D0 (en) | Peptides |